Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office has issued a patent allowance for PuraMed BioScience's over-the-counter analgesic LipiGesic M.
Subscribe to our email newsletter
The sublingual homeopathic migraine pain reliever is formulated as a non-aqueous gel containing feverfew and ginger.
LipiGesic M has established a significant efficacy profile in clinical studies concerning acute migraine conducted at three headache centers across the US.
PuraMed BioScience president and CEO Russell Mitchell said the patent allowance along with positive clinical trial results and recommendations prove that LipiGesic M is an effective treatment for migraine headache and associated symptoms.
"LipiGesic M does not require a prescription. The all-natural formulation outperforms the leading prescription medications while costing up to 75 percent less," Mitchell added.
"LipiGesic M gives migraineurs a powerful tool in the fight against migraines without the debilitating side effects, drowsiness, or rebound headaches caused by other chemically based prescription and over-the-counter migraine medications."
LipiGesic M is currently being evaluated in a clinical study for treatment of migraine in children and adolescents.
Company anticipates reporting the results in 2013.